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Abstract 
Aims: Cardiovascular (CV) disease risk prediction represents an increasing clinical challenge 
in the treatment of diabetes. We used a panel of vascular imaging, functional assessments and 
biomarkers reflecting different disease mechanisms to identify clinically useful markers of 
risk for CV events in subjects with type 2 diabetes mellitus (T2DM) with or without manifest 
cardiovascular disease (CVD). 
Methods and results: The study cohort consisted of 936 subjects with T2DM and a reference 
population of 487 non-diabetic subjects recruited at four European centers. The three-year CV 
event rate in subjects with T2DM was higher in those with (n=440) than in those without 
(n=496) manifest CVD at baseline (5.53 versus 2.15/100 life years, p<0.0001). New CV 
events in T2DM subjects with manifest CVD were associated with higher baseline levels of 
inflammatory biomarkers (interleukin-6, chemokine ligand 3 and pentraxin 3) and endothelial 
mitogens (hepatocyte growth factor and vascular endothelial growth factor A), while CV 
events in T2DM subjects without manifest CVD were associated with more severe baseline 
atherosclerosis as assessed by carotid ultrasonography. Conventional risk factors, as well as 
measurements of arterial stiffness and endothelial reactivity, were not associated with CV 
events. Similar associations with CV events were found in the non-diabetic subjects. 
Conclusions: Our observations demonstrate that markers of inflammation and endothelial 
stress reflects CV risk in T2DM subjects with manifest CVD, while the risk for CV events in 
T2DM subjects without manifest CVD is primarily related to the severity of atherosclerosis. 
Key words: diabetes, cardiovascular events, carotid ultrasound, biomarkers, risk assessment 
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Diabetes is an important risk factor for cardiovascular disease (CVD) and is associated with a 
two-fold excess risk of acute myocardial infarction (AMI) and stroke.1 A recent large Swedish 
registry study showed that although the incidence of CV events has declined substantially in 
subjects with diabetes between 1998 and 2014, it still remains significantly higher than in 
subjects without diabetes.2 With the worldwide adult prevalence of diabetes rising from 4.7% 
in 1980 to 8.5% in 2014 the CV complications of diabetes represents a major public health 
challenge.3 The increased CV risk associated with diabetes remains essentially the same when 
adjusting for conventional risk factors.1 Accordingly, traditional risk score calculators are less 
useful in diabetes.4, 5 This has not been a major clinical concern because most guidelines have 
considered all subjects with diabetes as having high risk based on studies demonstrating that 
the CV risk is equivalent to non-diabetic subjects with a previous coronary event.6 However, 
studies that are more recent have shown that the CV risk in type 2 diabetes mellitus (T2DM) 
is highly heterogeneous and that many subjects with T2DM have much lower risk of CVD 
than subjects with established CVD and no diabetes.7-10 Hence, there is an urgent need to 
improve CVD risk prediction in T2DM. 
The Innovative Medicine Initiative project SUMMIT (SUrrogate markers for Micro- and 
Macro-vascular hard endpoints for Innovative diabetes Tools) was initiated to novel markers 
for prediction of CV complications in diabetes. Given the poor risk prediction in diabetics 
based on traditional CV risk factors alone and the still elusive causes behind the increased CV 
risk in diabetics, we wanted to assess the ability of a panel of non-invasive vascular imaging, 
functional vascular tests and emerging biomarkers to predict CV risk in subjects with T2DM. 
To meet this end, we carried out the SUMMIT Vascular Imaging Prediction (SUMMIT VIP) 
study. As there is a growing population of T2DM patients with clinically manifest CVD that 
are at a very high risk for new events11 we included both subjects with and without prevalent 
CVD. To determine to what extent our findings would be specific for subjects with T2DM we 
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also included age and sex-matched non-diabetic subjects with or without prevalent CVD in 
the study. 
 
Methods are available in the on-line supplement 
 
Results 
The baseline investigation of SUMMIT VIP included 458 subjects with T2DM and CVD 
(myocardial infarction, stroke or lower extremity arterial disease), 527 subjects with T2DM 
but without clinically manifest CVD and 515 subjects without T2DM (245 with and 270 
without CVD). The clinical characteristics of the study cohort have been previously 
published.12 Fatal and non-fatal cardiovascular (CV) events were registered during a 3-year 
follow-up period. Seventy-seven subjects (5.1%) were excluded from the study due to lack of 
information of clinical events during follow-up. Of the remaining 1423 subjects 154 suffered 
a cardiovascular event during follow-up (3.6 CV events/100 life years). There were also 23 
deaths from non-cardiovascular causes and 9 death of unknown cause (supplemental table 1). 
Subjects with T2DM and manifest CVD at baseline had a more than two-fold higher CV 
event rate than those free of CVD at baseline (5.5 versus 2.2/100 life years, p<0.0001).  In the 
non-diabetic reference groups, the CV event rate during follow-up was also more than two-
fold higher in those with manifest CVD at baseline (4.8 versus 2.0/100 life years, p=0.002).   
 
Markers for CV events at follow up in subjects with T2DM and manifest CVD 
Occurrence of a new CV event in the T2DM/CVD group was associated with higher baseline 
HbA1c, but otherwise there were no difference in other conventional risk factors (table 1). 
4
Insulin treatment was more common among those with a new event. However, when 
including both HbA1c and insulin treatment in a binary logistic regression model together 
with age, sex, duration of diabetes, smoking, BMI, triglycerides, LDL, HDL and eGFR only 
HbA1c remained significantly associated with a new CV event (hazard ratio 1.03 (95%CI 
1.01-1.03). With the exception of an increased IMT in the left carotid bulb there were no 
significant differences in carotid IMT, total carotid plaque area, pulse wave velocity, 
endothelial reactivity or ABPI between those with and without a new CV event (table 2). 
However, baseline plasma levels of endothelial mitogens and biomarkers reflecting 
inflammation, such as IL-6 and CCL3, as well as matrix metalloproteinase (MMP)-12, N-
terminal prohormone of brain natriuretic peptide (NT-proBNP) and fatty acid binding protein 
(FABP)-4, were higher in subjects with a new event (table 3). In subjects with T2DM and 
manifest CVD the discrimination slope of a binary logistic regression model with IL-6 and 
risk factors (age, sex, duration of diabetes, current smokers, total cholesterol, HDL, HbA1c, 
systolic blood pressure and ethnicity) was significantly improved by 2.7 percentage points 
compared with a model without IL-6 (IDI 0.027 [95%CI 0.0064-0.048], p=0.010). The area 
under the receiver operating characteristic (AUROC) curve was significantly increased with 
the addition of IL-6 to the risk factor model (AUROC of IL-6 and risk factor model 0.68 
[95%CI 0.60-0.75], AUROC of risk factor model 0.60 [95%CI 0.51-0.69, p=0.020). Risk 
reclassification with the addition of IL-6 to the model was mainly downwards (figure S1 A-
B). 
 
Markers for CV events at follow up in T2DM subjects without manifest CVD 
There were no significant differences in conventional CV risk factors or medication between 
those with and without a CV event during follow-up in the T2DM/non-CVD group (table 1). 
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Those with a CV event had increased IMT in both the left and right bulb, the right common 
carotid artery (CCA), as well as an increased total carotid plaque area (table 2). Pulse wave 
velocity, endothelial reactivity and ABPI were not associated with the occurrence of CV 
events. Subjects with CV events also had higher baseline plasma levels of the apoptosis 
marker TRAIL receptor 2 and of Growth and Differentiation Factor (GDF)-15, but did not 
demonstrate the same elevation in endothelial mitogens and inflammatory biomarkers as 
T2DM subjects with manifest CVD that suffered a new event (table 3). In the T2DM/non-
CVD group the discrimination slope of a binary logistic regression model with right CCA 
IMT and risk factors (age, sex, duration of diabetes, current smokers, total cholesterol, HDL, 
HbA1c, systolic blood pressure and ethnicity) was significantly improved by 2.4 percentage 
points compare to a model without IMT (IDI right CCA IMT 0.024 [95%CI 0.0035-0.045]; 
p=0.022). Risk reclassification with the addition of right CCA IMT to the model was mainly 
downwards (figure S1 C-D). There was no significant difference in AUROC with the addition 
of right CCA IMT to the risk factor model (p=0.10). 
 
Markers for CV events at follow up in non-diabetic subjects with manifest CVD  
Subjects in the non-diabetic/CVD group that suffered a new event had higher baseline systolic 
blood pressure and increased IMT in the left carotid bulb, but otherwise there were no 
differences in conventional risk factors, medication or any of the vascular analyses as 
compared with those spared from a new event (tables 4 and 5). In line with observations in the 
T2DM/CVD group, endothelial mitogens and markers of inflammation, as well as MMP-12 
and NT-proBNP, were elevated in those with a new CV event (table 6). Tumor necrosis factor 
(TNF) receptor 1 and Fas, as well as GDF-15, were also elevated in those with a new event. 
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Markers for CV events at follow up in non-diabetic subjects without manifest CVD  
Subjects in the non-diabetic/non-CVD group that suffered a CV event had lower HDL and 
eGFR as well as higher serum creatinine (table 4). They were also characterized by increased 
bilateral carotid bulb IMT, right CCA IMT, total carotid plaque area, a lower right ABPI as 
well as by an increased pulse wave velocity (table 5). Moreover, those with a CV event also 
had higher plasma levels of IL-6, VEGF A, MMP-7, MMP-12, TNF receptor 1 and GDF-15 
(table 6). 
 
Discussion 
Using a panel of conventional risk factors, vascular assessments and emerging biomarkers, we 
demonstrate in the present study that different markers predict risk for CV events in T2DM 
patients with and without manifest CVD. T2DM subjects with manifest CVD that developed a 
new event had higher baseline plasma levels of pro-inflammatory cytokines, endothelial 
mitogens, MMP-12, FABP-4 and the cardiac stress marker NT-proBNP, but were not 
characterized by more severe atherosclerosis as assessed by carotid IMT (except from a 
marginally thicker IMT in left carotid bulb) or ABPI. The biological process that results in 
elevated levels of endothelial mitogens remains to be fully characterized but is likely to 
involve endothelial stress. Except for a higher HbA1c there were no differences in 
conventional risk factors between those with and without a new CV event. In general, a 
similar pattern was observed in the non-diabetic group with established CVD. Subjects with a 
recurrent event in this group also had higher baseline levels of pro-inflammatory cytokines, 
endothelial mitogens, MMP-12 and NT-proBNP. They also had higher baseline levels of 
biomarkers reflecting apoptosis as well as of GDF-15. Both NT-proBNP and GDF15 are 
established markers of CV risk.13, 14 Notably, NT-proBNP only predicted CV events in 
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subjects with established CVD in the present study, irrespective of diabetes status. Other 
studies have identified elevated NT-proBNP as a CV risk factor in subjects with T2DM,15 but 
to our knowledge it has previously not been shown that this primarily is the case for T2DM 
subjects with prevalent CVD. Subjects without diabetes that suffered a new event had 
increased carotid bulb IMT at baseline, but there was no difference in CCA IMT, total carotid 
plaque area or ABPI.  Increased arterial stiffness and endothelial dysfunction as assessed by 
reduced vasodilatation following transient ischemia are well-established vascular 
complications in diabetes and have been associated with increased CV risk.16-19 In 
accordance, subjects with T2DM were found to have increased pulse wave velocity and a 
lower reactive hyperaemia index at the SUMMIT VIP baseline investigation.12 In spite of this, 
neither of these measures predicted the occurrence of a new event in subjects with established 
CVD in the present study.  
 
Development of a CV event in T2DM subjects without manifest CVD at baseline was 
associated with increased carotid atherosclerosis as assessed by the CCA and carotid bulb 
IMT, as well as by increased total carotid plaque area at the baseline investigation. However, 
biomarkers were less good predictors with only GDF-15 and the apoptosis marker TRAIL 
receptor 2 being higher in those with a CV event. Moreover, there were no differences in 
conventional risk factors between those with and without a CV event. In he non-diabetic 
group without manifest CVD at baseline we found that those that developed a CV event had 
increased carotid IMT in the right CCA as well as in the left carotid bulb, increased carotid 
total plaque area, decreased right ABPI, increased pulse wave velocity, as well as higher 
levels of several known CV risk biomarkers including IL-6, MMP-12 and GDF-15. They also 
had lower HDL and signs of reduced kidney function. In essence, CV events demonstrated a 
clear association with established risk factors in this group. 
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Our observations are in accordance with previous observations that conventional risk factors 
are poor predictors of CV events in subjects with T2DM, however they suggest some 
important alternatives.  We found that biomarkers reflecting inflammation, as well as 
endothelial and cardiac stress, are predictors of CV events in subjects with diabetes and 
manifest CVD, while carotid IMT is a better predictor of risk in diabetic subjects without 
manifest CVD. Similar, but less distinct associations were observed in non-diabetic subjects 
with and without manifest CVD at baseline. Increased carotid IMT is a well-established CV 
risk factor in the general population.20 In accordance, T2DM subjects with manifest CVD at 
the baseline investigation had significantly greater carotid IMT than those without manifest 
CVD.12 Hence, there seems to be a clear association between atherosclerosis severity and CV 
risk in subjects with T2DM, but this association diminishes in subjects with manifest CVD. 
One possible explanation to this could be that a more intense medical intervention in subjects 
with manifest CVD allows other risk factor mechanisms than those traditionally associated 
with atherosclerosis progression to become more important as cause of CV events.21 Hence, 
biomarkers that associate with CV events in this group could provide information regarding 
such alternative mechanisms. In the present studies we found that subjects with new events 
had higher baseline levels of pro-inflammatory biomarkers and endothelial mitogens 
suggesting the presence of an inflammatory state involving endothelial stress that persist in 
the presence of statin treatment. In this context it is interesting to note that the recently 
published Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial 
showed that IL-1 antibody treatment lowered the rate of recurrent events in patients with 
history of myocardial infarction and elevated hs-CRP in spite of statin treatment.22 The 
mechanisms that maintain vascular inflammation in statin-treated patients remains to fully 
characterized but may involve factors such as altered shear stress over stenotic plaques, intra-
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plaque accumulation of cholesterol crystals, autoimmune responses against modified plaque 
antigens and chronic infections.23 
In conclusion, our observations demonstrate that markers of inflammation and endothelial 
stress are elevated in T2DM subjects with manifest CVD that develop a new event suggesting 
that these patients may benefit from novel anti-inflammatory CV therapy. The risk for CV 
events in T2DM subjects without manifest CVD is primarily related to the severity of 
atherosclerosis. 
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Table 1. Baseline clinical characteristics for subjects with diabetes with or without a cardiovascular event during follow-up 
 CVD at baseline (n=440) No CVD at baseline (n=496) 
 No CV event (n=367) CV event (n=73) P No CV event (n=464) CV event (n=32) P 
Age (years) 69.4±8.5 69.3±8.7 ns 66.5±8.7 68.2±6.1 ns 
Sex (% males) 73.4 65.6 ns 62.5 62.5 ns 
Current smokers (%) 9.5 16.4 ns 9.1 15.6 ns 
Duration of diabetes (years) 12.1±8.6 13.5±8.8 ns 9.1±7.0 11.5±6.3 ns 
BMI (kg/m-2) 29.9±4.7 30.7±5.6 ns 30.6±5.4 30.4±4.8 ns 
Medications       
Insulin (%) 29.3 45.7 0.007 15.8 25.0 ns 
Statin (%) 88.9 80.6 (0.05) 61.3 75.0 ns 
ACE inhibitors (%) 54.1 44.4 ns 38.5 34.4 ns 
Metformin (%) 65.0 61.4 ns 71.4 81.3 ns 
Betablockers (%) 57.4 56.9 ns 17.8 9.4 ns 
Metabolic factors       
HbA1c (mmol/mmol) 57.7±12.9 62.8±18.7 0.036 56.1±13.6 59.3±12.9 ns 
LDL (mmol/L) 2.06±0.77 2.08±0.75 ns 2.41±0.93 2.24±0.76 ns 
HDL (mmol/L) 1.20±0.36 1.19±0.33 ns 1.32±0.38 1.30±0.41 ns 
Triglycerides (mmol/L) 1.42 (1.02-2.08) 1.45 (1.05-1.84) ns 1.35 (1.00-1.97) 1.40 (0.90-2.43) ns 
Blood pressure       
Systolic (mmHg) 138±20 140±17 ns 136±18 137±17 ns 
Diastolic (mmHg) 76±10 74±9 ns 78±10 77±9 ns 
Renal function       
Serum creatinine (mol/L) 94.1±31.7 97.9±71.2 ns 79.9±20.4 82.5±17.9 ns 
eGFR (mL/min-1 per 1.73m2) 74.8±26.9 78.0±27.6 ns 85.1±20.7 81.0±20.0 ns 
 
Variables with normal distribution are shown as mean±standard deviation and skewed variables as median and interquartile range. Statistical 
comparisons between subjects with and without events during follow-up were done using Students´ t-test for variables with normal distribution 
and with Mann-Whitney U-test for skewed variables.  
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Table 2. Baseline vascular measurements in subjects with diabetes with or without a cardiovascular event during follow-up 
 CVD at baseline (n=440) No CVD at baseline (n=496) 
 No CV event (n=367) CV event (n=73) P No CV event (n=464) CV event (n=32) P 
CCA IMT, right (mm) 0.97±0.25 0.92±0.20 ns 0.89±0.20 1.00±0.23 0.002 
Carotid bulb IMT, right (mm) 1.14 (0.96-1.62) 1.38 (1.01-1.84) ns 1.03 (0.87-1.24) 1.28 (0.85-1.55) (0.07) 
CCA IMT, left (mm) 0.97±0.25 0.87±0.25 ns 0.92±0.24 1.07±0.49 0.001 
Carotid bulb IMT, left (mm) 1.13 (0.95-1.47) 1.27 (1.03-1.67) 0.045 1.05 (0.88-1.27) 1.20 (0.95-1.78) 0.04 
Total plaque area (mm2) 30.4 (15.3-61.4) 36.0 (17.6-68.6) ns 19.5 (9.5-40.5) 30.4 (16.1-92.2) 0.01 
Pulse wave velocity (m/s) 11.8±3.2 11.3±2.3 ns 10.9±2.6 11.6±2.5 ns 
Reactive hyperemia index 2.10±0.56 2.16±0.55 ns 2.20±0.65 2.04±0.79 ns 
ABPI, right 1.11±0.22 1.05±0.28 (0.07) 1.20±0.15 1.20±0.32 ns 
ABPI, left 1.11±0.23 1.10±0.28 ns 1.18±0.28 1.18±0.29 ns 
 
CCA; common carotid artery, IMT; intima-media thickness, ABPI; ankle brachial pressure index. Variables with normal distribution are shown 
as mean±standard deviation and skewed variables as median and interquartile range. Statistical comparisons between subjects with and without 
events during follow-up were done using Students´ t-test for variables with normal distribution and with Mann-Whitney U-test for skewed 
variables. 
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Table 3. Baseline biomarkers in subjects with diabetes with or without a cardiovascular event during follow-up 
 CVD at baseline (n=440) No CVD at baseline (n=496) 
 No CV event (n=367) CV event (n=73) P No CV event (n=464) CV event (n=32) P 
Inflammation       
IL-6 42.8 (29.8-68.1) 58.5 (42.1-93.5) 0.00005 34.1 (23.8-52.7) 39.5 (24.2-58.0) ns 
CCL3 (MIP-1) 4.8 (3.9-5.9) 5.1 (4.2-6.7) 0.008 4.6 (3.9-5.9) 4.7 (3.9-5.4) ns 
Pentraxin 3 2.1 (1.7-2.6) 2.3 (2.0-2.7) 0.043 2.1 (1.7-2.6) 2.1 (1.8-2.6) ns 
Endothelial mitogens       
Hepatocyte growth factor 122 (95-148) 134 (107-169) 0.029 110 (88-135) 112 (89-146) ns 
Placental growth factors 189 (153-253) 207 (156-250) ns 167 (138-204) 184 (143-223) (0.08) 
VEGF A 1520 (1199-1934) 1624 (1246-2131) 0.045 1409 (1136-1783) 1558 (1199-1824) ns 
Matrix proteolysis       
MMP-3 2.6 (2.1-3-5) 2.6 (2.2-3.3) ns 2.4 (1.9-2.9) 2.2 (2.0-2.6) ns 
MMP-7 517 (333-780) 545 (342-750) ns 410 (282-580) 539 (347-691) ns 
MMP-12 172 (11-249) 204 (147-289) 0.025 125 (92-180) 130 (102-234) (0.09) 
Apoptosis       
TNF receptor 1 7231 (5743-9153) 7033 (5873-9793) ns 6295 (5220-7591) 6451 (5433-7899) ns 
TRAIL receptor 2 3.9 (2.7-5.3) 4.2 (2.8-5.4) ns 3.3 (2.5-4.1) 4.0 (3.1-4.4) 0.039 
Fas 231 (186-274) 218 (179-276) ns 210 (175-247) 212 (169-254) ns 
Other       
NT-proBNP 26.2 (14.3-43.6) 38.6 (20.5-58.9) 0.001 14.3 (9.8-26.0) 16.2 (10.3-22.7) ns 
GDF-15 1458 (1044-2154) 1541 (1143-2073) ns 1121 (830-1632) 1483 (1180-1898) 0.005 
FABP-4 10.7 (7.8-14.9) 13.7 (8.5-19.8) 0.01 9.6 (7.3-12.6) 10.6 (7.6-17.2) ns 
 
CCL; chemokine ligand 3, MIP1-; macrophage inflammatory protein 1-, VEGF A; vascular endothelial growth factor A, MMP; matrix 
metalloproteinase, TNF; tumor necrosis factor, TRAIL; tumor necrosis factor-related apoptosis-inducing ligand, NT-proBNP; N-terminal 
prohormone of brain natriuretic peptide, GDF-15; growth differentiation factor-15, FABP-4; fatty acid binding protein-4. All values are arbitrary 
units shown as median and interquartile range. Statistical comparisons between subjects with and without events during follow-up were done on 
log2-transformed values using Students´ t-test.   
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Table 4. Baseline clinical characteristics for non-diabetic controls with or without a cardiovascular event during follow-up 
 CVD at baseline (n=234) No CVD at baseline (n=253) 
 No CV event (n=200) CV event (n=34) P No CV event (n=238) CV event (n=15) P 
Age (years) 69.1±8.4 71.1±7.1 ns 64.6±10.6 70.0±7.2 (0.05) 
Sex (% males) 71.5 41.1 ns 55.9 26.7 ns 
Current smokers (%) 9.5 14.7 ns 8.9 20.0 ns 
BMI (kg/m-2) 27.9±4.1 27.5±4.0 ns 26.7±4.0 27.7±2.8 ns 
Medications       
Statin (%) 85.5 88.2 ns 21.6 6.7 ns 
ACE inhibitors (%) 46.0 32.3 ns 11.1 0 ns 
Betablockers (%) 53.0 64.7 ns 10.7 6.7 ns 
Metabolic factors       
HbA1c (mmol/mmol) 39.7±4.8 41.2±3.8 ns 38.5±3.9 38.5±4.2 ns 
LDL (mmol/L) 2.27±0.76 2.41±0.98 ns 3.18±0.84 3.18±0.73 ns 
HDL (mmol/L) 1.36±0.40 1.41±0.41 ns 1.57±0.42 1.29±0.33 0.013 
Triglycerides (mmol/L) 1.15 (0.87-1.60) 1.25 (0.89-1.75) ns 1.20 (0.86-1.60) 1.40 (1.20-2.07) ns 
Blood pressure       
Systolic (mmHg) 132±16 142±24 0.046 132±16 137±18 ns 
Diastolic (mmHg) 75±9 76±10 ns 78±9 79±12 ns 
Renal function       
Serum creatinine (mol/L) 86.0±20.2 83.6±26.6 ns 78.3±16.3 90.2±22.5 0.008 
eGFR (mL/min-1 per 1.73m2) 79.1±18.6 77.4±17.1 ns 84.3±15.7 75.7±20.4 0.046 
 
Variables with normal distribution are shown as mean±standard deviation and skewed variables as median and interquartile range. Statistical 
comparisons between subjects with and without events during follow-up were done using Students´ t-test for variables with normal distribution 
and with Mann-Whitney U-test for skewed variables. 
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Table 5. Baseline vascular measurements in subjects without diabetes with or without a cardiovascular event during follow-up 
 CVD at baseline (n=234) No CVD at baseline (n=253) 
 No CV event (n=200) CV event (n=34) P No CV event (n=238) CV event (n=15) P 
CCA IMT, right (mm) 0.90±0.24 0.99±0.28 (0.07) 0.85±0.18 1.07±0.38 0.038 
Carotid bulb IMT, right (mm) 1.07 (0.8-1.35) 1.26 (0.95-1.82) 0.047 0.98 (0.85-1.18) 1.08 (0.93-1.49) ns 
CCA IMT, left (mm) 0.92±0.25 0.95±0.21 ns 0.87±0.24 0.99±0.26 (0.07) 
Carotid bulb IMT, left (mm) 1.09 (0.93-1.33) 1.37 (1.15-1.63) 0.0003 1.01 (0.84-1.24) 1.29 (0.95-1.53) 0.026 
Total plaque area (mm2) 24.7 (1.1-68.1) 24.2 (15.2-76.9) ns 18.1 (9.2-41.4) 40.5 (17.7-84.7) 0.014 
Pulse wave velocity (m/s) 10.4±2.6 11.1±3.3 ns 9.6±2.4 11.0±2.4 0.045 
Reactive hyperemia index 2.29±0.66 2.21±0.55 ns 2.48±0.70 2.18±0.54 ns 
ABPI, right 1.14±0.19 1.08±0.20 ns 1.18 ±0.14 1.09 ±0.11 0.019 
ABPI, left 1.13±0.18 1.12±0.21 ns 1.18±0.14 1.18±0.11 ns 
 
CCA; common carotid artery, IMT; intima-media thickness, ABPI; ankle brachial pressure index. Variables with normal distribution are shown 
as mean±standard deviation and skewed variables as median and interquartile range. Statistical comparisons between subjects with and without 
events during follow-up were done using Students´ t-test for variables with normal distribution and with Mann-Whitney U-test for skewed 
variabels. 
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Table 6. Baseline biomarkers in subjects without diabetes with or without a cardiovascular event during follow-up 
 CVD at baseline (n=234) No CVD at baseline (n=253) 
 No CV event (n=200) CV event (n=34) P No CV event (n=238) CV event (n=15) P 
Inflammation       
IL-6 32.4 (22.0-51.3) 42.5 (27.4-69.4) 0.009 29.9 (19.3-47.4) 57.9 (35.4-93-5) 0.0004 
CCL3 (MIP1-) 4.7 (3.7-5.8) 5.9 (4.5-6.7) 0.004 4.6 (3.9-5.6) 5.0 (4.3-6.2) ns 
Pentraxin 3 2.0 (1.7-2.4) 1.9 81.7-2.7) ns 2.0 (1.7-2.4) 1.9 (1.6-2.39 ns 
Endothelial mitogens       
Hepatocyte growth factor 109 (86-133) 122 (101-164) 0.026 99 (79-122) 114 (92-124) ns 
Placental growth factors 177 (145-229) 211 (168-249) 0.02 168 (135-203) 191 (162-239) (0.07) 
VEGF A 1243 (-1031-1641) 1489 (1176-2048) 0.019 1375 (1081-1852) 1624 (1280-1842) 0.042 
Matrix proteolysis       
MMP-3 2.5 (1.9-3.2) 2.8 (2.1-3.7) (0.051) 2.4 (1.9-3.1) 2.8 (2.3-3.2) ns 
MMP-7 431 (309-635) 545 8391-683) (0.058) 358 (272-506) 580 (366-674) 0.013 
MMP-12 145 (105-212) 190 (125-279) 0.026 113 (80-155) 184 (118-277) 0.00005 
Apoptosis       
TNF receptor 1 5955 (5008-7383) 6382 (5636-8172) 0.047 5793 (4738-6937) 5957 (5481-8350) 0.039 
TRAIL receptor 2 3.1 (2.3-3.9) 3.4 (2.6-5.2) (0.091) 3.0 (2.2-3.7) 3.3 (2.6-4.9) ns 
Fas 204 (171-244) 226 (195-273) 0.006 195 (164-239) 198 (173-236) ns 
Other       
NT-proBNP 25.8 (15.3-41.4) 42.9 (25.2-63.9) 0.001 17. 0 (10.0-27.1) 20.2 (8.4-26.2) ns 
GDF-15 826 (635-1121) 1176 (816-1424) 0.01 673 (518-887) 875 (630-1420) 0.012 
FABP-4 9.0 (7.0-11.5) 9.8 (8.4-13.89 (0.066) 8.6 (6.8-11.2) 9.8 (5.9-14.59 ns 
 
CCL; chemokine ligand 3, MIP1-; macrophage inflammatory protein 1-, VEGF A; vascular endothelial growth factor A, MMP; matrix 
metalloproteinase, TNF; tumor necrosis factor, TRAIL; tumor necrosis factor-related apoptosis-inducing ligand, NT-proBNP; N-terminal 
prohormone of brain natriuretic peptide, GDF-15; growth differentiation factor-15, FABP-4; fatty acid binding protein-4. All values are arbitrary 
units shown as median and interquartile range. Statistical comparisons between subjects with and without events during follow-up were done on 
log2-transformed values using Students´ t-test.
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